Larry Alphs Selected Research

Headache (Headaches)

1/2018	Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
3/2015	Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
10/2011	Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
8/2011	Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial.
5/2011	Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
11/2010	Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Larry Alphs Research Topics

Disease

52	Schizophrenia (Dementia Praecox) 01/2023 - 01/2003
18	Psychotic Disorders (Schizoaffective Disorder) 10/2022 - 01/2003
7	Weight Gain 11/2016 - 12/2009
6	Headache (Headaches) 01/2018 - 11/2010
6	Mania (Manias) 03/2016 - 11/2009
5	Pain (Aches) 10/2018 - 05/2011
5	Bipolar Disorder (Manic Depressive Psychosis) 10/2011 - 11/2009
4	Sleep Initiation and Maintenance Disorders (Insomnia) 05/2015 - 11/2010
3	Chronic Disease (Chronic Diseases) 01/2018 - 01/2012
3	Sleepiness 11/2016 - 11/2010
2	Major Depressive Disorder (Major Depressive Disorders) 10/2019 - 01/2019
2	Mental Disorders (Mental Disorder) 01/2018 - 04/2017
1	Movement Disorders (Movement Disorder) 01/2023
1	Parkinson Disease (Parkinson's Disease) 01/2023
1	Treatment-Resistant Depressive Disorder 01/2019
1	Injection Site Reaction 10/2018
1	Dizziness (Lightheadedness) 01/2018
1	Nausea 01/2018
1	Substance-Related Disorders (Drug Abuse) 01/2018
1	Orthostatic Hypotension (Postural Hypotension) 11/2016
1	Hyperprolactinemia 07/2015
1	Hyperglycemia 07/2015
1	Psychomotor Agitation (Akathisia) 05/2015
1	Nasopharyngitis 03/2015
1	Parkinsonian Disorders (Parkinsonism) 01/2013
1	Tremor (Tremors) 01/2013
1	Dyskinesias (Dyskinesia) 01/2013
1	Delirium 02/2011

Drug/Important Bio-Agent (IBA)

43	Paliperidone Palmitate FDA Link 01/2023 - 12/2009
35	Antipsychotic Agents (Antipsychotics)IBA 01/2023 - 01/2004
15	Risperidone (Risperdal Consta)FDA LinkGeneric 08/2018 - 12/2009
8	asenapine FDA Link 11/2013 - 01/2007
7	Olanzapine (Zyprexa)FDA Link 11/2013 - 01/2003
3	Antidepressive Agents (Antidepressants)IBA 01/2019 - 10/2011
3	Glucose (Dextrose)FDA LinkGeneric 11/2016 - 01/2012
2	ProlactinIBA 11/2016 - 01/2012
2	Clozapine (Clozaril)FDA LinkGeneric 01/2004 - 01/2003
1	EsketamineIBA 01/2018
1	HDL LipoproteinsIBA 11/2016
1	Cholinergic Antagonists (Anticholinergics)IBA 11/2016
1	CholesterolIBA 11/2016
1	TabletsIBA 11/2016
1	cyclo(Arg-Pro) (CI 4)IBA 07/2015
1	LipidsIBA 02/2014
1	Insulin (Novolin)FDA Link 02/2014
1	Anti-Anxiety Agents (Anxiolytics)IBA 10/2011
1	Aripiprazole (Abilify)FDA Link 11/2010
1	Dihydrotachysterol (AT 10)IBA 04/2010
1	Haloperidol (Haldol)FDA LinkGeneric 04/2010

Therapy/Procedure

30	Injections 01/2023 - 12/2009
9	Therapeutics 01/2019 - 01/2003
3	Drug Therapy (Chemotherapy) 01/2019 - 10/2011
3	Time-to-Treatment 01/2018 - 12/2014
3	Secondary Prevention 03/2015 - 01/2012
2	Patient Readmission 06/2014 - 10/2013
1	Length of Stay 10/2019
1	Aftercare (After-Treatment) 10/2011